The Hepatitis D drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatitis D. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatitis D and features dormant and discontinued products.
GlobalData tracks 26 drugs in development for Hepatitis D by 21 companies/universities/institutes. The top development phase for Hepatitis D is preclinical with nine drugs in that stage. The Hepatitis D pipeline has 23 drugs in development by companies and three by universities/ institutes. Some of the companies in the Hepatitis D pipeline products market are: Assembly Biosciences, Replicor and Vir Biotechnology.
The key targets in the Hepatitis D pipeline products market include Sodium/Bile Acid Cotransporter (Cell Growth Inhibiting Gene 29 Protein or Na(+)/Bile Acid Cotransporter or Na(+)/Taurocholate Transport Protein or Sodium/Taurocholate Cotransporting Polypeptide or Solute Carrier Family 10 Member 1 or SLC10A1), Hepatitis B Virus Surface Antigen (HBsAg), and Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1).
The key mechanisms of action in the Hepatitis D pipeline product include Sodium/Bile Acid Cotransporter (Cell Growth Inhibiting Gene 29 Protein or Na(+)/Bile Acid Cotransporter or Na(+)/Taurocholate Transport Protein or Sodium/Taurocholate Cotransporting Polypeptide or Solute Carrier Family 10 Member 1 or SLC10A1) Inhibitor with eight drugs in Filing rejected/Withdrawn. The Hepatitis D pipeline products include four routes of administration with the top ROA being Subcutaneous and eight key molecule types in the Hepatitis D pipeline products market including Small Molecule, and Monoclonal Antibody.
Hepatitis D overview
Hepatitis D, also known as the delta virus, is an infection that causes the liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite, and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs, and being infected while pregnant.
For a complete picture of Hepatitis D’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
